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A practical enantioselective protecting group-free four-step route to the key quinolizidinone 6 from 
phenylglycinol-derived bicyclic lactam 1 is reported. The organometallic addition reaction upon 6 takes 
place stereoselectively to give 1-ethyl-4-substituted quinolizidines 4-epi-207I and 7-9. Following a 
similar synthetic sequence, 9a-epi-6 is also accessed. However, the addition of Grignard reagents upon 
9a-epi-6 proceeds in a non-stereoselective manner. In order to gain insight into the different 10 
stereochemical outcome in the two series, theoretical calculations on the iminium salts A and B have been 
performed.  The study concludes that the addition of the hydride, which is the step that determines the 
configuration of the final products, occurs in a stereoelectronic controlled manner. The theoretical study 
is in agreement with the experimental results.  
Introduction 15 
The extracts from the skin of certain poisonous frogs and toads 
contain alkaloids showing promising biomedical activities. So far, 
none of these alkaloids has been reported from any other natural 
source. Most of them contain as a common structural feature an 
azabicyclic "izidine" nucleus, e. g. disubstituted pyrrolizidines, di- 20 
and trisubstituted indolizidines, or disubstituted quinolizidines.1 
Among them, 1,4-disubstituted quinolizidines2 are a relatively 
new class of alkaloids that have been isolated in minute quantities. 
Their structures have been partially elucidated based on the GC-
MS and GC-FTIR spectra, the latter showing significant Bohlmann 25 
bands3 indicating that the hydrogens at positions 4 and 9a are cis. 
The relative configuration at position 1 is only tentative and the 
absolute configuration of the stereocenters is unknown. As total 
synthesis is required for structural proof, it would be highly 
desirable to develop general asymmetric methodologies to easily 30 
access these biologically interesting compounds. 
There are currently about 20 compounds assigned to this 
particular structural family of amphibian alkaloids4 including 
seven 1-ethylquinolizidines representatives (Figure 1). Among 
them, six show a 1,4-trans relative configuration while alkaloid  35 
(-)-207I is unique, with substituents being 1,4-cis. 
 
Figure 1 1-Ethyl-4-substituted quinolizidines. 
 
The relative stereochemistry of natural quinolizidine (-)-207I 40 
was determined in 1997 by Momose’s group by comparison of the 
GC-MS and GC-FIT spectra of the 1-epi-207I isomer synthesized 
by them and the natural alkaloid.5 In 2003, Toyooka and co-
workers published the first enantioselective synthesis of (+)-207I, 
the enantiomer of the alkaloid, thus determining the absolute 45 
stereochemistry of the natural product.6 More recently, the same 
research team reported the synthesis of 233A, 235U and 251AA 
alkaloids.7 Although pioneering, these syntheses suffer from the 
drawback of requiring a considerable number of synthetic steps, 
leading to a low yield of the final product, partly due to the use of 50 
protecting groups. Therefore, a general and efficient procedure 
providing access to different 1,4-disubstituted quinolizidine 
alkaloids would be of interest. 
Interestingly from the biological point of view, 1-epi-207I 
selectively blocks α7 nicotinic receptors (IC50 = 0.6µM).8 In 55 
contrast, alkaloids 233A, 235U and 251AA block the responses 
mediated by α7 and α4β2 nicotinic receptors without any 
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selectivity observed between both subtypes. Comparing the latter 
compounds with 1-epi-207I led the authors to conclude that the α7 
subtype selectivity of 1,4-disubstituted quinolizidines is 
remarkably dependent on the structure of the C4 side chain. 
Increasing the length of the 4-moiety beyond three carbons appears 5 
to markedly reduce potency and selectivity at the α7 receptor.  
In this paper we disclose a general protocol for the 
enantioselective construction of these biologically attractive 
structural motifs using chiral bicyclic lactams as enantiomeric 
scaffolds.9 Taking into account the aforementioned biological 10 
studies, we planned to attach a 1 to 3 carbon chain at the C4 
position of the azabicyclic nucleus.  
Results and Discussion 
Retrosynthetic analysis 
Our retrosynthetic analysis is briefly outlined in Scheme 1. We 15 
envisioned that the alkyl group at C-4 could be installed by a 
stereoselective addition of an organometallic reagent to the 
carbonyl amide group of a 1-ethyl quinolizidine derivative. This 
bicyclic lactam was surmised to be constructed by a ring-closing 
metathesis reaction of a monocyclic diallylated derivative. In turn, 20 
the required trisubstituted 2-piperidone would be obtained by 
alkylation of (5S,6S)-6-allyl-5-ethyl-2-piperidone, whose 
enantiomer had been previously synthesized by our group by an  
α-amidoalkylation reaction10 of the enantiomer of the chiral 






















Scheme 1 Retrosynthetic analysis. 
 
Preparation of (5S,6S)-6-allyl-5-ethyl-2-piperidone (3) 
As previously reported by our group in the enantiomeric series, the 30 
TiCl4–promoted addition of allyltrimethylsilane to 1 occurs 
stereoselectively, with inversion of the configuration at the C8a to 
afford a 9:1 mixture of cis-6-allyl-5-ethyl disubstituted lactam 2 
and its C6 epimer, 6-epi-2. The absolute stereochemistry of 2 was 
unambiguously confirmed by X-Ray crystallographic analysis 35 
(Figure 2). The configuration of the 5 and 6 stereocenters remains 
in the final product since both of them are configurationally stable 

























Scheme 2 Reagents and conditions: (i) Allyltrimethylsilane (2.0 40 
equiv), TiCl4 (4.0 equiv), CH2Cl2, 0 ºC to rt, 16 h, 2 (77%) and 6-
epi-2 (7%); (ii) Na (metal), NH3 (l), 30 min, –33 ºC, 81%; (iii) NaH 
(2.0 equiv), allyl bromide (1.1 equiv), THF, 0 ºC to rt, 24 h, 75%; 
(iv) (a) NaOH (10 equiv), O2 (1 atm), MTBE, 40 ºC, 24 h; (b) Allyl 
bromide (1.25 equiv), rt, 19 h, 69% overall; (v) Second-generation 45 
Grubbs cat. (2.5 mol %), CH2Cl2, rt, 8 h, 87%; (vi) H2 (1 atm), 10% 
Pd/C, MeOH, rt, 18 h, 87%.  
 
Figure 2 X-Ray structure of (5S,6S)-6-Allyl-5-ethyl-1-[(1S)-2-
hydroxy-1-phenylethyl]-2-piperidone (2). Molecules are linked 50 
along the a-axis of the crystal through the hydrogen bond O8-
H8···O2i (d(O···O) = 2.722(3)Å, angle(O-H···O) = 171.2º, i=[ x-
½, ½-y, z ]) forming zigzag motifs. 
 
Preparation of azabicyclic compound 6 55 
To construct the second six-membered ring from 2, removal of the 
2-phenylethanol moiety and installation of a second allyl moiety 
was required. To this end, treatment of 2 with Na/liquid NH3 
afforded 3 in 81% yield. Transformation of 3 into the diolefinic 
compound 4 was accomplished by deprotonation with NaH 60 
followed by alkylation with allyl bromide. More conveniently, we 
developed a one-pot two-step process from 2 to 4 involving 
removal of the 2-phenylethanol moiety and alkylation in the same 
vessel in basic media by sequential treatment with O2 and allyl 
bromide (69% overall yield).12 With all the carbon atoms installed 65 
in compound 4 a ring-closing metathesis reaction could be 
performed and the required six-membered piperidine ring 
accessed. A second-generation ruthenium Grubbs catalyst 
mediated this reaction from 4 to generate 5 (87%) under mild 
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conditions.13 Chemoselective reduction of 5 employing catalytic 
hydrogenation was accomplished to give 6, which is a valuable 
synthetic intermediate for the formation of the targeted diversely 
4-substituted 1-ethylquinolizidines.  
 5 
Addition of Grignard reagents to azabicyclic compound 6 
With bicyclic lactam 6 in hand, the stage was set to execute the 
installation of an alkyl substituent at carbon 4. To this end, a one-
pot procedure, involving the reaction of 6 with Grignard reagents 
followed by dehydration to the corresponding iminium salts and 10 
reduction to the final products, was studied.  
In order to access alkaloid (-)-207I we first considered the 
addition of allylmagnesium bromide. Interestingly, while there are 
several reports dealing with the addition of organometallic 
reagents to the 2-quinolizidinone nucleus,14 to the best of our 15 
knowledge, the addition of an allylmetallic reagent is 
unprecedented.15 Only after much experimentation did we find that 
the reaction indeed occurs using an excess of Grignard reagent (4 
equiv) in the presence of anhydrous CeCl3.16 
Being aware that the reduction step would be responsible for the 20 
stereochemistry of the final product, different reducing agents 
were evaluated. While reduction with NaBH3CN or NaBH(AcO)3 
gave inseparable mixtures of (-)-207I and its C4-epimer, 4-epi-
207I, (34:66 and 23:77, respectively), NaBH4 and DIBAL-H 
furnished 4-epi-207I with a high degree of diastereoselectivity 25 




Scheme 3 Reagents and conditions: (i) (a) CeCl3 (4.0 equiv), 30 
allylmagnesium bromide (4.0 equiv), THF, rt, 18 h; (b) NaBH4 
(1.25 equiv), MeOH, AcOH, –78 ºC, 30 min, 58%, d.r. = 97:3. 
 
In order to access C-4 analogues of the alkaloid (-)-207I, the 
addition of different Grignard reagents was studied. In all cases, 35 
the alkyl chain introduced was limited to a length of up to three 
carbon atoms, taking into account previous biological studies.7,8 To 
this end, an excess of (2-methylallyl)magnesium bromide was 
added to 6, followed by treatment with NaBH4 to give 7 and 4-epi-
7 (96:4) in 56% yield. Following similar experimental conditions, 40 
a propyl and a methyl chain were also introduced to 
stereoselectively furnish 8 and 9 in 64 and 69% yield, respectively 
(Scheme 4).  
 
Scheme 4 Reagents and conditions: (i) (a) CeCl3 (2.0 equiv), 2-45 
methylallylmagnesium chloride (8.0 equiv) or propylmagnesium 
bromide (4.0 equiv), THF, rt, 18 h; (b) NaBH4 (1.25 equiv), 
MeOH, AcOH, –78 ºC, 30 min, 56%, 7; 69%, 9.  
 
Structural elucidation of the final bicyclic amines  50 
The absolute configuration of the C-4 stereogenic center in (-)-
207I and 4-epi-207I was assigned by correlation of the NMR data 
of these two compounds with those reported for the previously 
synthesized enantiomer, (+)-207I.6 
Worthy of note, in 4-epi-207I the peaks corresponding to C-6 55 
and C-9a are about 5 and 3 ppm more shielded, respectively, than 
in (-)-207I (Table 1). This shielding probably reflects the γ-gauche 
effect due to an axial disposition of the allyl substituent in 4-epi-
207I.  Comparison of the 13C NMR and 1H NMR (Table 2) of 
compounds 7-9 with that of 4-epi-207I led to the depicted 60 
configuration being assigned to the C-4 stereocenter of these new 
products (Scheme 4).18 
 





7 8 9 
1 40.6 41.9 41.8 42.1 41.8 
4 64.2 50.9 49.7 51.2 46.7 
9a 66.7 61.1 61.1 61.2 60.8 
6 53.1 50.1 50.3 50.2 50.1 
[a] δ values from reference 6. 
 





7 8 9 
1 1.55 1.53 1.54 1.52 1.58 
4 1.88 3.00 3.03 2.88 2.98 
9a 1.96 2.93 2.94 2.93 2.92 
6eq 3.33 3.34 3.32 3.30 3.27 
6ax 1.54 2.71 2.69 2.66 2.67 
[a] δ values from reference 6. 70 
 
In fact, full geometry optimization of 9 and its hypothetical C4 
epimer (4-epi-9), performed with the B3LYP density functional 
method using the 6-31G(d) basis set, revealed that while both 
compounds were in a chair-chair conformation, only 9 displayed 75 
its 4-methyl group in an axial valence (Figure 3), while the methyl 
group in 4-epi-9 was in an equatorial disposition (Figure 4). Thus, 
theoretical calculations are in concordance with the 13C-NMR 
observations.   
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Figure 3 The most stable conformation of compound 9 (γ-gauche 
effects are indicated). 
 
Figure 4 The most stable conformation of hypothetical compound 5 
4-epi-9. 
 
Synthesis of 9a-epi derivatives of 4-substituted 2-
ethylquinolizidines 
With compounds 6-epi-2 in hand (Scheme 2), we decided to go a 10 
step further and apply the developed procedure to prepare 9a-epi-
6 to study the stereochemical outcome of the Grignard addition 
reactions in compounds with a C9a R configuration. Thus, the 
introduction of an allyl group on the piperidone nitrogen of 6-epi-
2 gave compound 6-epi-4 in 56% yield. Subsequent treatment with 15 
Grubbs second-generation catalyst furnished 9a-epi-5, which was 
hydrogenated to give 9a-epi-6 with yields comparable to those 























Scheme 5 Reagents and conditions: (i) (a) NaOH (10 equiv), O2 (1 
atm.), MTBE, 40 ºC, 24 h; (b) allyl bromide (1.25 equiv), rt, 19 h, 
56% overall; (ii) Second-generation Grubbs cat. (3 mol %), 
CH2Cl2, rt, 6 h, 90%; (iii) H2 (1 atm.), 10% Pd/C, MeOH, rt, 16 h, 25 
98%. 
 
The addition reaction of allylmagnesium bromide in the 
presence of anhydrous CeCl3 to 9a-epi-6 followed by NaBH4 
reduction occurs in a non steroselective manner to give a 1:1 30 
mixture of 10 and 9a-epi-207I. Similar results were observed in the 
reaction of 9a-epi-6 with methylmagnesium bromide, yielding an 
equimolecular mixture of the two possible products. These results 
are in striking contrast with the stereochemical behaviour of the 
additions previously studied in 6, which occurred with very high 35 
stereoselectivity.  
The structural assignation of these quinolizidines was done by 
comparison with the spectroscopic data of compound 10 whose 





R = CH2=CHCH2 10 9a-epi-207I










Scheme 6 Reagents and conditions: (i) (a) CeCl3 (2.0 equiv), 
allylmagnesium bromide or methylmagnesium bromide (4.0 
equiv), THF, rt, 18 h; (b) NaBH4 (1.25 equiv), MeOH, AcOH, –78 
ºC, 30 min, 10 and 9a-epi-207I (54%); 11 and 4-epi-11 (48%). 45 
 
Theoretical considerations of the stereochemical outcome in 
the introduction of the C-4 substituent 
As previously mentioned, the stereochemistry of the 
organometallic addition reaction is determined by the attack of the 50 
hydride to the iminium salt. In order to gain insight into the 
stereochemistry of the final products, studies on the relative 
stability of different conformers of the iminium ion intermediates 
when a methyl substituent is attached were considered (Scheme 7). 
Indeed, exploration of the different conformational states for the 55 
iminium salts A and B, at the B3LYP/6-31 (G) level, gave two 
main possible conformations, depending on the disposition 
adopted by the ethyl substituent. Starting from A, the non 
substituted six-membered ring of the quinolizidine adopts a chair 
conformation in both iminium forms. As expected, the substituted 60 
ring adopts a half-chair conformation with the C3, C4, N and C9a 
atoms in the same plane, with the ethyl group either in an 
equatorial, AI, or axial disposition, AII (Figures 5 and 6), AI being 
more stable by 3.1 Kcal/mol. This fact could be ascribed to a 1,3-
diaxial destabilizing interaction in AII between the axial ethyl 65 
substituent and the axial protons at positions 3 and 9. On the basis 
of these findings, the stereochemical outcome of the addition 
reaction can be explained considering an axial attack of the 
hydride, under stereoelectronic control,20 at the electrophilic 
carbon of the lowest-energy iminium ion intermediate, AI. This 70 
directed nucleophile attack dictates an S configuration in the newly 
created stereocenter, as depicted in Figure 5. 
In a similar fashion, in the two possible conformations of the 
iminium salt B, the non-substituted ring adopts a chair 
conformation, whereas the substituted ring shows a half-chair 75 
conformation with the C3, C4, N and C9a atoms in the same plane. 
However, in the iminium salt B both possible conformations, BI, 
with the ethyl group in an equatorial disposition, and BII, with the 
ethyl group in an axial disposition, are energetically similar (∆E < 
1 Kcal/mol) (Figures 7 and 8). The smaller energy gap between 80 
both conformations may be indicative of a relative stabilization of 
the conformation BII in comparison with AII because only one 
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1,3-diaxial destabilizing interaction (ax-Et/ax-H3) is found in the 
former. Consequently, as both conformations are of similar 
energies, the stereoelectronic controlled addition of the hydride 
upon the iminium salt can occur on both BI and BII, yielding 






Scheme 7 Intermediate iminium salts. 
 
Figure 5 Two views of the most stable conformation of the 10 
iminium salt intermediate AI and indication of the hydride 
stereocontrolled addition.  
Figure 6 Two views of the most stable conformation of the 
iminium salt intermediate AII. 1,3-Diaxial destabilizing 15 
interactions are indicated.  
 
Figure 7 Two views of the most stable conformation of the 
iminium salt intermediate BI and indication of the hydride 
stereocontrolled addition.  20 
 
Figure 8 Two views of the most stable conformation of the 
iminium salt intermediate BII and indication of the hydride 
stereocontrolled addition. 1,3-Diaxial destabilizing interaction is 
indicated.  25 
Conclusions 
In conclusion, we have developed a straightforward 
enantioselective synthesis of potentially biologically interesting 1-
ethyl-4-substituted quinolizidines without using protecting groups. 
The stereochemistry of the stereocenters is defined by the use of 30 
(S)-phenylglycinol as the source of chirality and by two 
stereocontrolled reactions, an α-amidoalkylation and an 
organometallic addition. Compounds in the 9a-epi series have been 
efficiently obtained following the synthetic sequence developed in 
the original series. However, the final organometallic addition 35 
reaction proved to be not stereoselective. In order to rationalize the 
different stereochemical outcome in the Grignard addition 
reactions in the two series, theoretical calculations on the iminium 
salts were performed indicating that the addition of the hydride 
occurs in a stereoelectronic controlled fashion.  40 
Experimental Section 
General Methods  
NMR spectra were recorded in CDCl3 at 300 or 400 MHz (1H) and 
75.4 or 100.6 MHz (13C), and chemical shifts are reported in δ 
values downfield from TMS or relative to residual chloroform 45 
(7.26 ppm, 77.0 ppm) as an internal standard. Data are reported in 
the following manner: chemical shift, multiplicity, coupling 
constant (J) in hertz (Hz), integrated intensity. Multiplicities are 
reported using the following abbreviations: s, singlet; d, doublet; 
dd, doublet of doublets; t, triplet; m, multiplet; br s, broad signal, 50 
app, apparent. Evaporation of solvents was accomplished with a 
rotatory evaporator. Melting points were determined in a capillary 
tube and are uncorrected. Thin-layer chromatography was done on 
SiO2 (silica gel 60 F254), and the spots were located by UV, 1% 
aqueous KMnO4 or iodoplatinate (for tertiary amines). 55 
Chromatography refers to flash column chromatography and was 
carried out on SiO2 (silica gel 60, SDS, 230-400 mesh) or Al2O3 
(Aluminium oxide 90 active basic, Merck). Mass spectra were 
recorded on a LTQ spectrometer using electrospray (ES+) 
ionization techniques.  60 
 
(5S,6S)-6-Allyl-5-ethyl-1-[(1S)-2-hydroxy-1-phenylethyl]-2-
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TiCl4 (20 mL, 182.12 mmol) was slowly added to a cooled (0 ºC) 
solution of 1 (11.17 g, 45.53 mmol) in anhyd CH2Cl2 (90 mL) and 
the mixture was stirred for 15 min. Allyltrimethylsilane (14.5 mL, 
91.06 mmol) was added in 3 portions and the resulting mixture was 
warmed at rt and stirred for 16 h. The mixture was poured onto ice 5 
and the aqueous layer was extracted with CH2Cl2. The combined 
organic extracts were dried, filtered and concentrated to give a 
90:10 (1H NMR) mixture of 2 and 6-epi-2, which was purified by 
column chromatography (Biotage Si 40M 2197-1, CH2Cl2-MeOH 
99.5:0.5 to 97:3) to yield 2  (10.02 g, 77%) and C6-epi-2 (0.87 g, 10 
7%). 2:10 m.p 75.0-76.0 ºC (cyclohexane/pentane); [α]22D = +21.3 
(c 0.45, CHCl3). Anal. Calcd for C18H25NO2: C, 75.22; H, 8.77; N, 
4.87. Found: C, 75.29; H, 8.68; N, 4.94 %. (5S,6R)-6-Allyl-5-
ethyl-1-[(1S)-2-hydroxy-1-phenylethyl]-2-piperidone, (6-epi-
2). IR (NaCl) 3383, 2958, 1624 (s, NCO), 1452 cm-1; 1H NMR 15 
(400 MHz, CDCl3) δ 0.62 (t, J = 8.2 Hz, 3H, CH2CH3), 1.01 (m, 
1H, CH2CH3), 1.17 (m, 1H, CH2CH3), 1.51 (m, 1H, H-4), 1.61 (m, 
1H, H-5), 1.99 (m, 1H, H-4), 2.28 (m, 1H, CH2CH=), 2.41-2.46 
(m, 3H, H-3, CH2CH=), 3.06 (dm, J = 10.5 Hz, 1H, H-6), 3.96 (br 
s, 1H, OH), 4.16 (m, 1H, H-2‘), 4.24 (m, 1H, H-2‘), 5.01 (d, J = 20 
4.5 Hz, 1H, CH=CH2), 5.05 (m, 1H, CH=CH2), 5.41 (dd, J = 8.1, 
5.1 Hz, 1H, H-1‘), 5.57 (m, 1H, CH=CH2), 7.26-7.37 (m, 5H, H-
Ar); 13C NMR (100.6 MHz) δ 11.3 (CH2CH3), 22.2 (C-4), 24.3 
(CH2CH3), 28.5 (C-3), 35.4 (C-5), 39.3 (CH2CH=), 59.1 (C-6), 
62.7 (C-1’), 63.6 (C-2’), 117.7 (CH=CH2), 127.8 (CHAr),128.3 25 
(2CHAr), 128.5 (2CHAr), 134.0 (CH=CH2), 136.9 (CAr), 172.4 
(NCO); [α]22D  –19.6 (c 1.0, CHCl3); HRMS C18H26NO2 [M+H]+ 
288.1958; found, 288.1958.  
 
(5S,6S)-6-Allyl-5-ethyl-2-piperidone, (3).  30 
Into a three-necked, round-bottomed flask equipped with a cold-
finger condenser charged with dry ice-acetone was condensed NH3 
(ca. 150 mL) at –78 °C. The temperature was allowed to rise to –
33 °C and a solution of alcohol 2 (1.00 g, 3.48 mmol) in THF (5 
mL) was added, followed by the addition of sodium metal in small 35 
portions until the blue colour persisted. After the mixture was 
stirred at –33 °C for 30 min, the reaction was carefully quenched 
by the addition of solid NH4Cl until the blue colour disappeared. 
The mixture was stirred at rt overnight, the residue was partitioned 
between H2O and CH2Cl2, and the aqueous layer was extracted 40 
with CH2Cl2. The combined organic extracts were dried, filtered 
and concentrated. The resulting residue was chromatographed 
(SiO2, hexane-EtOAc 1:1 to 1:2) to give 3 as a white solid (0.47 g, 
81 %) and 2 (0.07 g, 7%). IR (NaCl) 3208, 2959, 1664 (s, NCO) 
cm-1; 1H NMR (300 MHz, COSY) δ 0.96 (t, J = 7.4, 3H, (CH2CH3), 45 
1.52–1.24 (m, 2H, CH2CH3), 1.70–1.86 (m, 3H, H-4, H-5), 2.02–
2.12 (m, 1H, CH2CH=), 2.21–2.40 (m, 3H, CH2CH=, H-3), 3.39-
3.50 (m, 1H, H-6), 5.16 (d, J = 7.6, 1H, CH=CH2), 5.20 (d, J = 0.7, 
1H, CH=CH2), 5.65–5.82 (m, 1H, CH=CH2), 5.83 (br s, 1H, NH); 
13C NMR (75.4  MHz) δ 11.6 (CH2CH3) 20.7 and 22.7 (C-50 
4/CH2CH3), 29.1 (C-3), 36.3 (CH2CH=), 37.3 (C-5), 54.8 (C-6), 
119.1 (CH=CH2), 134.0 (CH=CH2), 172.0 (NCO); [α]22D = –66.32 
(c 1.03, MeOH); HRMS C10H18NO [M+H]+ 168.1383; found, 
168.1382. 
 55 
(5S,6S)-1,6-Diallyl-5-ethyl-2-piperidone, (4).  
Method A. A solution of 3 (656 mg, 3.93 mmol) in THF (20 mL) 
was added via cannula to NaH (320 mg, 7.85 mmol, 60% 
dispersion in mineral oil). After 15 min, the reaction mixture was 
cooled (0 ºC) and allyl bromide (380 µL, 4.32 mmol) was added 60 
with a syringe pump over 60 min. Then, the mixture was warmed 
up at rt and stirred for 24 h. The reaction mixture was cooled (0 
ºC), quenched by the addition of water (10 mL), and extracted with 
EtOAc. The combined organic extracts were dried and 
concentrated to give a residue, which was chromatographed 65 
(hexane-EtOAc 4:1) to furnish 4 (613 mg, 75%) as a yellow oil.  
 
Method B. In a round-bottomed flask equipped with a 1 gallon gas 
bag of O2, an excess of freshly ground NaOH (2.78 g, 69.6 mmol) 
was added to a solution of 2 (2.00 g, 6.96 mmol) in MTBE (20 70 
mL). The mixture was heated at 40 ºC and stirred slowly at this 
temperature for 24 h. The progress of reaction was monitored by 
TLC and, when 2 was consumed, the gas bag was disconnected 
and the reaction mixture was cooled to rt. Allyl bromide (0.75 mL, 
8.70 mmoL) was slowly added and stirring was continued for 75 
additional 19 h at rt. The solvent was removed, the residue was 
partitioned between H2O and CH2Cl2, and the aqueous layer was 
extracted with CH2Cl2. The organic extracts were washed with 
saturated NH4Cl solution, dried and concentrated to give a residue, 
which was purified by column chromatography (hexane-EtOAc 80 
4:1) to yield 4 (994 mg, 69%) as a yellow oil. IR (NaCl film) 2932, 
1642 (s, NCO) cm-1; 1H NMR (300 MHz, COSY, HSQC) δ 0.93 
(t, J = 7.4 Hz, 3H CH2CH3), 1.31-1.42 (m, 2H, -CH2CH3), 1.58-
1.83 (m, 3H, H-4 and H-5), 2.23 (m, 1H, H-1’), 2.36-2.49 (m, 3H, 
H-3 and H-1’), 3.35 (m, 1H, H-1’’), 3.40 (m, 1H, H-6), 4.71 (dddd, 85 
J = 15.3, 4.2, 1.5, 1.5 Hz, 1H, H-1’’), 5.04-5.16 (m, 4H, H-3’, H-
3’’), 5.69-5.90 (m, 2H, H-2’, H-2’’); 13C NMR (100.6 MHz) δ 11.8 
(CH2CH3), 22.6 (CH2CH3), 25.4 (C-4), 30.6 (C-3), 34.1 (C-1‘), 
40.6 (C-5), 49.0 (C-1‘‘), 58.7 (C-6), 116.9 (=CH2), 117.4 (=CH2), 
133.2 (CH=CH2), 135.7 (CH=CH2), 170.0 (CON); [α]22D = –95.56 90 
(c 1.0, MeOH); HRMS C13H22NO [M+H]+ 208.1696; found, 
208.1696. Anal. Calcd for C13H21NO .¼ H2O: C, 73.72; H, 10.23; 
N, 6.61. Found: C, 73.96; H, 10.18; N, 6.18 %. Note: Trace 
amounts of (5S,6S)-6-allyl-1-[(S)-2-(allyloxy)-1-phenylethyl)]-
5-ethylpiperidin-2-one were also isolated. IR (NaCl) 2961, 1641 95 
(s, NCO), 1452 cm-1; 1H NMR (400 MHz, CDCl3, HSQC, COSY) 
δ 0.88 (t, J = 7.4 Hz, 3H, CH2CH3), 1.24-1.37 (m, 2H, CH2CH3), 
1.60 (m, 1H, H-4), 1.73-1.87 (m, 2H, H-4, H-5), 1.96 (dddt, J = 
14.6, 7.2, 4.5, 1.3 Hz, 1H, CH2CH=), 2.21 (m, 1H, CH2CH=), 2.45-
2.54 (m, 2H, H-3), 3.46 (m, 1H, H-6), 4.01 (ddt, J = 7.0, 5.5, 1.4 100 
Hz, 2H, OCH2CH=), 4.08 (dd, J = 6.1, 1.6 Hz, 2H, H-2’), 4.83 (m, 
1H, C6-CH2CH=CH2), 4.87 (app t, J = 1.4 Hz, 1H, 
C6CH2CH=CH2), 5.16 (m, app dq, J = 10.4, 1.3 Hz, 1H, 
OCH2CH=CH2), 5.23-5.28 (m, 2H, H-1’, OCH2CH=CH2), 5.48 
(m, 1H, CH2CH=), 5.89 (ddt, J = 17.2, 10.4, 5.5 Hz, 1H, 105 
OCH2CH=CH2), 7.24-7.36 (m, 5H, H-Ar); 13C NMR (100.6 MHz) 
δ 11.9 (CH2CH3), 22.2 (C-4), 25.7 (CH2CH3), 30.6 (C-3), 34.8 
(CH2CH=), 41.3 (C-5), 58.8 (C-6), 60.1 (C-1’), 70.6 (C-2’), 71.9 
(OCH2CH=CH2), 116.5 (CH=CH2), 116.8 (OCH2CH=CH2), 127.6 
(CHAr), 128.4 (4CHAr), 134.6 (CH2CH=), 135.6 110 
(C6CH2CH=CH2), 138.4 (CAr), 171.0 (NCO); HRMS C21H30NO2 
[M+H]+ 328.2271; found, 328.2270. 
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(1S,9aS)-1-Ethyl-4-oxo-1,2,3,6,9,9a-hexahydro-4H-
quinolizine, (5).  
Ruthenium catalyst (Grubbs 2nd generation, 245 mg, 0.29 mmol) 
was added to a solution of 4 (2.40 g, 11.58 mmol) in CH2Cl2 (300 
mL) and the solution was stirred at rt for 8 h. The mixture was 5 
concentrated and the resulting residue was purified by column 
chromatography (Al2O3, hexane-EtOAc 3:1 to 3:2) to afford 5 
(1.80 g, 87%), which revealed to be unstable. IR (NaCl) 2960, 
2932, 1662 (s, NCO), 1634 cm-1; 1H NMR (300 MHz, CDCl3, 
COSY, HSQC) δ 0.96 (t, 3H, J = 7.4 Hz, -CH2CH3), 1.36 (m, 2H, 10 
-CH2CH3), 1.50-1.75 (m, 3H, 2xH2 and H-1), 1.80-2.22 (m, 2H, 
H-9), 2.30-2.55 (m, 2H, H-3), 3.39 (app d, J = 18.0 Hz, 1H, H-6), 
3.58 (td, J = 11.6, 4.5 Hz, 1H, H-9a), 4.95 (app d, J = 18.0 Hz, 1H, 
H-6), 5.68 (m, 1H, H-7), 5.73 (m, 1H, H-8); 13C NMR (75.4  MHz, 
CDCl3) δ 11.8 (CH2CH3), 22.1 (C-2), 24.3 (CH2CH3), 26.3 (C-9), 15 
32.3 (C-3), 38.3 (C-1), 43.1 (C-6), 55.9 (C-9a), 124.8 and 125.0 
(C-7/C-8), 168.8 (NCO); [α]22D = –44.3 (c = 1.20, MeOH); HRMS 
C11H18NO [M+H]+ 180.1383; found, 180.1379. 
 
(1S,9aS)-1-Ethyl-4-oxo-1,2,3,6,7,8,9,9a-octahydro-4H-20 
quinolizine, (6).  
10% Pd/C (60 mg) was added to a solution of 5 (1.20 g, 6.69 mmol) 
in MeOH (20 mL) and the mixture was stirred under hydrogen 
atmosphere for 18 h. Then, the crude mixture was filtered through 
a Celite and the solvent was evaporated to afford a residue, which 25 
was purified by bulb-to-bulb distillation (6 Torr, 160-170 ºC) to 
obtain 6 (1.05 g, 87%) as a colourless liquid. IR (NaCl) 2934, 2863, 
1642 (s, NCO), 1466 cm-1; 1H NMR (400 MHz, CDCl3, COSY, 
HSQC) δ 0.87 (t, 3H, J = 7.4 Hz, CH2CH3), 1.16-1.64 (m, 9H, 
CH2CH3, H-2, H-7, H-8, H-9), 1.78 (m, 1H, H-1), 1.87 (m, H7), 30 
2.27 (m, 1H, H-3), 2.30-2.41 (m, 2H, H-3, H-6), 3.24 (dd, 1H, J = 
11.8, 5.1 Hz, H-9a), 4.65 (ddd, 1H, J = 12.8, 3.9, 1.9Hz, H-6); 13C 
NMR (100.6 MHz) δ 11.7 (CH2CH3), 22.9 (C-8), 24.1 (CH2CH3), 
25.1 (C-7), 25.7 (C-2), 26.2 (C-9), 32.3 (C-3), 38.7 (C-1), 44.6 (C-
6), 60.6 (C-9a), 168.6 (NCO); [α] 22D = –49.1 (c 2.0, CHCl3); MS-35 
EI m/z 181 M+ (37), 125 (51), 97 (100), 83 (43), 55 (30); HRMS 
C11H20NO [M+H]+, 182.1539; found, 182.1541. Anal. Calcd for 
C11H19NO.1/3 H2O: C, 70.57; H, 10.58; N, 7.48. Found: C, 70.23; 
H, 10.14; N, 7.32 %. 
 40 
(5S,6R)-1,6-Diallyl-5-ethyl-2-piperidone, (6-epi-4). 
Following the procedure for the preparation of 4 (method B), from 
lactam 6-epi-2 (2.10 g, 7.27 mmol), NaOH (2.91 g, 72.7 mmol), 
MTBE (25 mL), and allyl bromide (0.79 mL, 9.09 mmol), 
compound 6-epi-4 (0.84 g, 56%) was obtained after column 45 
chromatography (hexane-EtOAc 4:1). IR (NaCl) 2932, 1642 (s, 
NCO) cm-1; 1H NMR (400 MHz, COSY, HSQC) δ 0.91 (t, J = 7.4 
Hz, 3H, CH2CH3), 1.32-1.43 (m, 2H, CH2CH3), 1.58 (m, 1H, H-
4), 1.69 (m, 1H, H-5), 1.98 (m, 1H, H-4), 2.22-2.51 (m, 4H, 2xH-
3 and 2xH-1’), 3.20 (dt, J = 9.3, 3.3 Hz, 1H, H-6), 3.37 (dd, J = 50 
15.0, 7.7 Hz, 1H, H-1’’), 4.67 (ddt, J = 15.0, 4.7, 1.6 Hz, 1H, H-
1‘‘), 5.07-5.21 (m, 4H, H-3’ and H-3’’), 5.62-5.82 (m, 2H, H-2’ 
and H-2’’); 13C NMR (100.6 MHz) δ 11.3 (CH2CH3), 20.3 (C-4), 
24.1 (-CH2CH3), 27.9 (C-3), 35.4 (C-5), 37.3 (C-1’), 47.5 (C-1’’), 
59.3 (C-6), 117.3 (C-3‘ or C-3‘‘), 117.8 (C-3‘ or C-3’’), 133.2 (C-55 
2’’ or C-2’), 135.9 (C-2’’ or C-2’), 169.6 (CON); [α]22D = +44.1 (c 
1.0, CHCl3); HRMS calcd for C13H22NO [M+H]+, 208.1696; 
found, 208.1695. Anal. Calcd. for C13H21NO.1/5 H2O: C, 74.07; 




Following the procedure for the preparation of 5, from lactam 6-
epi-4 (0.62 g, 2.99 mmol) and 2nd generation Grubbs catalyst (76 
mg, 0.09 mmol, 0.03 equiv) in CH2Cl2 (100 mL), compound 9a-65 
epi-5 (0.48 g, 90%) was obtained after column chromatography 
(Al2O3, hexane-EtOAc 1:1 to 0:1). 9a-Epi-5 revealed to be 
unstable. 1H NMR (400 MHz, CDCl3, COSY, HSQC) δ 0.96 (t, 
3H, J = 7.3 Hz, CH2CH3), 1.36 (m, 1H, CH2CH3), 1.45-1.55 (m, 
2H, H-1, H-2), 1.60 (m, 1H, CH2CH3), 1.92 (m, 1H, H-2), 2.11 (m, 70 
1H, H-9), 2.26 (m, 1H, H-9), 2.32 (m, 1H, H-3), 2.45 (m, 1H, H-
3), 3.21 (ddd, J = 9.9, 5.8, 3.8 Hz, 1H, H-9a), 3.40 (app d, J = 18.5 
Hz, 1H, H-6), 4.83 (app d, J = 18.5 Hz, 1H, H-6), 5.68 (m, 1H, H-
7), 5.77 (m, 1H, H-8); 13C NMR (100.6 MHz, CDCl3) δ 11.3 
(CH2CH3), 22.9 (C-2), 25.1 (CH2CH3), 30.7 (C-3), 32.5 (C-9), 40.4 75 
(C-1), 42.5 (C-6), 57.7 (C-9a), 124.1 and 124.3 (C-7/C-8), 169.5 





 Following the procedure for the preparation of 6, from lactam 6-
epi-5 (315 mg, 1.76 mmol), 10% Pd/C (32 mg) and MeOH (9.0 
mL), compound 9a-epi-6 (310 mg, 98%) was obtained as a 
colourless liquid after bulb-to-bulb distillation (6 Torr, 160-170 85 
ºC). IR (NaCl) 2933, 1643 (s, NCO), 1463 cm-1; 1H NMR (400 
MHz, CDCl3, COSY, HSQC) δ 0.95 (t, 3H, J = 7.4 Hz, CH3CH2-), 
1.14-1.47 (m, 6H, CH2CH3), H-1, H-2, H-8, H-9), 1.55-1.68 (m, 
2H, CH2CH3, H-9), 1.83-1.97 (m, 3H, H-2, H-7, H-8), 2.23 (m, 1H, 
H-3), 2.35 (td, 1H, J = 12.8, 2.9 Hz, H-6), 2.44 (dt, 1H, J = 17.3, 90 
4.4 Hz, H-3), 2.89 (ddd, 1H, J = 11.3, 6.9, 2.4 Hz, H-9a), 4.81 (ddt, 
1H, J = 12.8, 4.0, 2.9 Hz, H-6); 13C NMR (100.6 MH) δ 11.3 
(CH2CH3), 23.5 (C-2*), 24.7 (C-8*), 25.3 (CH2CH3), 25.4 (C-9*), 
31.4 (C-3), 33.0 (C-7), 41.4 (C-1), 42.9 (C-6), 61.9 (C-9a), 169.0 
(NCO); [α]22D = –27.5 (c 1.0, CHCl3); HRMS calcd for C11H20NO 95 
[M+H]+ 182.1539; found, 182.1538. Anal. Calcd for C11H19NO. 
1/4 H2O: C, 71.12; H, 10.58; N, 7.54. Found: C, 71.36; H, 10.49; 
N, 6.94 %. 
 
General procedure for the addition of organometal reagents. 100 
Anhydrous CeCl321 (2.0 equiv) was added to a solution of 6 (1 
equiv) in anhyd THF. The resulting suspension was vigorously 
stirred at rt for 1 h.  Grignard reagent was added dropwise (4.0-8.0 
equiv) over 30 min and the mixture was stirred for additional 18 h. 
MeOH was added to quench the reaction and the mixture was 105 
cooled at -78 ºC. NaBH4 (1.25 equiv) and AcOH (0.3 mL) were 
added and the mixture was stirred at –78 ºC for 30 min. The 
mixture was concentrated and the residue was partitioned between 
Et2O and 1N HCl solution. Then, the acidic aqueous phase was 
washed with Et2O and basified with 4N NaOH solution (pH=12-110 
14). The resulting suspension was centrifuged (800 g for 30 min at 
rt) and the supernatant was extracted with CH2Cl2.22 The combined 
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organic extracts were dried, filtered, concentrated and analysed by 
GC-MS. The crude product was purified by flash chromatography 
(Al2O3).  
 
(1S,4R,9aS)-4-Allyl-1-ethylquinolizidine, (4-epi-207I), 5 
(1S,4S,9aS)-4-allyl-1-ethylquinolizidine, (-)-207I and (1S,9aS)-
4,4-diallyl-1-ethylquinolizidine. 
Following the general procedure, from lactam 6 (300 mg, 1.66 
mmol), CeCl3 (1.63 g, 6.62 mmol), allylmagnesium bromide (7.0 
mL, 7.0 mmol, 1.0 M solution in Et2O), THF (7 mL), and NaBH4 10 
(78 mg, 2.7 mmol), a 97:3 diastereomeric mixture of 4-epi-207I 
and (-)-207I (GC-MS) was obtained. Traces of diallylated 
quinolizidine were also detected. 4-epi-207I (198 mg, 58%) was 
obtained after column chromatography (Al2O3, hexanes-EtOAc 
95:5 to 85:15). 4-epi-207I. IR (NaCl) 2957, 2928, 2856, 1456, 908 15 
cm-1; 1H NMR (400 MHz, CDCl3, COSY, HSQC) δ 0.87 (t, 3H, J 
= 7.4 Hz, CH3), 1.13-1.74 (m, 12H, CH2CH3, H-1, H-2, H-3, H-7, 
H-8, H-9), 1.88 (m, app dd, 1H, J = 12.7, 2.5 Hz, H-7), 2.14 (m, 
1H, CH2CH=), 2.37 (m, 1H, CH2CH=), 2.71 (td, 1H, J = 13.6, 2.5 
Hz, H-6ax.), 2.93 (m, 1H, H-9a), 3.00 (m, 1H, H-4), 3.34 (app d 1H, 20 
J = 13.6 Hz, H-6eq.), 4.98-5.10 (m, 2H, -CH=CH2), 5.83 (dddd, J = 
16.8, 10.2, 7.7, 6.6 Hz, 1H, CH=CH2); 13C NMR (75.4  MHz) δ 
11.8 (CH3), 18.0 (CH2), 19.3 (CH2), 25.2 (CH2), 25.7 (C-7), 29.7 
(CH2), 31.3 (CH2), 36.9 (CH2CH=), 41.9 (C-1), 50.1 (C-6), 50.9 
(C-4), 61.1 (C-9a), 116.5 (CH=CH2), 135.7 (CH=CH2); [α]22D = 25 
+14.4 (c 0.5, CH2Cl2); MS-EI m/z 206 (1), 167 (14), 166 (100), 110 
(12), 55 (3); HRMS calcd for C14H26N [M+H]+ 208.2060; found, 
208.2061. (-)-207I. 13C NMR spectra of (-)-207I (from a mixture 
of 4-epi-207I and (-)-207I) was coincident with that described 
previously in the literature;6 MS-EI m/z 206 M+ (1), 167 (12), 166 30 
(100), 136 (4), 110 (8), 55 (3). (1S,9aS)-4,4-diallyl-1-
ethylquinolizidine. 1H NMR (300 MHz, CDCl3, COSY) δ 0.89 (t, 
3H, J = 7.4 Hz, CH2CH3), 1.12-1.94 (m, 13H, CH2CH3, H-1, H-2, 
H-3, H-7, H-8, H-9), 2.24 (app d, 4H, J = 7.4 Hz, CH2CH=), 2.54 
(m, 1H, H-9a), 2.61 (app t, 1H, J = 11.4 Hz, H-6ax.), 3.12 (app d, 35 
1H, J = 11.4 Hz, H-6eq.), 5.03-5.19 (m, 4H, CH2CH=CH2), 5.86 
(m, 2H, CH2CH=CH2); 13C NMR (75.4  MHz) δ 12.0 (CH2CH3), 
22.7 (CH2), 25.1 (CH2), 26.5 (CH2), 28.7 (CH2), 36.9 (CH2), 43.6 
(2xCH2CH=), 44.1 (CH2), 45.5 (C-1), 47.5 (C-6), 59.1 (C-9a), 73.5 
(C-4), 118.3 (2xCH=CH2), 134.0 (2x CH=CH2); MS-EI m/z 224 40 
(34), 110 (3), 85 (6), 84 (100), 69 (5), 56 (6), 55 (6); HRMS calcd 
for C14H32NO [M+H2O]+ 266.2478; found, 266.2478.  
 
(1S,4R,9aS)-1-Ethyl-4-(2-methylallyl)quinolizidine, (7).  
Following the general procedure, from lactam 6 (50 mg, 0.28 45 
mmol), CeCl3 (140 mg, 0.55 mmol), 2-methylallylmagnesium 
chloride (3 mL, 2.20 mmol, 0.7 M solution in THF), THF (1.5 mL), 
and NaBH4 (14 mg, 0.35 mmol), a 96:4 diastereomeric mixture of 
7 and 4-epi-7 (GC-MS) was obtained. Pure 7 (34 mg, 56%) was 
obtained after column chromatography (Al2O3, hexane-EtOAc 50 
90:10 to 75:25). 7. IR (NaCl) 2956, 2926, 2855, 1734, 1460, 1377 
cm-1; 1H NMR (400 MHz, CDCl3, COSY, HSQC) δ 0.87 (t, 3H, J 
= 7.4 Hz, CH2CH3), 1.10-1.70 (m, 12H, CH2CH3, H-1, H-2, H-3, 
H-7, H-8, H-9), 1.73 (s, 3H, CCH3), 1.81-1.90 (m, 2H, H-7, CH2C), 
2.52 (dd, 1H, J = 13.0, 3.7 Hz, CH2C), 2.69 (td, 1H, J = 13.6, 2.6 55 
Hz, H-6ax.), 2.94 (app d, 1H, J = 12.7 Hz, H-9a), 3.03 (m, 1H, H-
4), 3.32 (app d, J = 13.6 Hz, H-6eq.), 4.71 (br s, 1H, =CH2), 4.77 
(br s, 1H, =CH2); 13C NMR (100.6 MHz) δ 11.9 (CH2CH3), 19.7 
(CH2), 22.7 (CCH3), 24.8 (CH2), 25.4 (CH2), 25.6 (C-7), 29.7 
(CH2), 30.3 (CH2), 40.7 (CH2C), 41.8 (C-1), 49.7 (C-4), 50.3 (C-60 
6), 61.1 (C-9a), 112.5 (=CH2), 143.7 (CH2C); MS-EI m/z 220 (1), 
167 (13), 166 (100), 110 (10), 55 (3); HRMS calcd for C15H27N 
[M+H]+, 222.2216; found, 222.2219. 4-epi-7: MS-EI m/z 221 (13), 
220 (12), 206 (10), 192 (18), 167 (12), 166 (100), 164 (16), 136 
(11), 110 (14), 84 (35), 83 (11), 82 (15), 67 (10), 55 (10). 65 
 
(1S,4S,9aS)-1-Ethyl-4-propylquinolizidine, (8).  
Following the general procedure, from lactam 6 (90 mg, 0.50 
mmol), CeCl3 (250 mg, 1.0 mmol), propylmagnesium bromide 
(1.0 mL, 2.0 mmol, 2.0 M solution in Et2O), THF (2.5 mL) and 70 
NaBH4 (25 mg, 0.63 mmol), a 99:1 diastereomeric mixture of 8 
and 4-epi-8 (GC-MS) was obtained. Pure amine 8 (67 mg, 64%) 
was isolated after column chromatography (Al2O3, hexane-EtOAc 
95:5 to 80:20). 8. IR (NaCl) 2958, 2928, 2858, 1461, 1276 cm-1; 
1H NMR: (400 MHz, CDCl3,  COSY, HSQC) δ 0.86 (t, 3H, J = 7.4 75 
Hz, CH3CH2), 0.91 (t, 3H, J = 7.1 Hz, CH3CH2CH2C4), 1.10-1.30 
(m, 10H), 1.36-1.75 (m, 6H), 1.87 (app d, 1H, J = 14.6, H-7), 2.66 
(td, 1H, J = 13.5, 2.7, H-6ax.), 2.88 (m, 1H, H-4), 2.93 (app d, 1H, 
J = 14.1, H-9a), 3.30 (app d, 1H, J = 13.5, H-6eq.); 13C NMR (100.6 
MHz) δ 11.8 (CH2CH3), 14.7 (CH2CH2CH3), 18.5 (CH2), 18.5 80 
(CH2), 19.3 (CH2), 25.3 (CH2), 25.8 (C-7), 25.9 (CH2), 29.7 (CH2), 
31.3 (CH2), 34.6 (CH2), 42.0 (C-1), 50.0 (C-6), 50.8 (C-4), 61.1 
(C-9a); MS-EI m/z 209 M+ (2), 167 (13), 166 (100), 110 (7), 84 
(4); [α]22D = +22.2 (c 1.0, CHCl3); HRMS calcd for C14H27N 
[M+H]+ 210.2216; found, 210.2218. 4-epi-8. MS-EI m/z 209 (2), 85 
167 (21), 166 (100), 138 (6), 110 (12), 84 (5), 55 (6).  
 
(1S,4S,9aS)-1-Ethyl-4-methylquinolizidine, (9).  
Following the general procedure, from lactam 6 (90 mg, 0.50 
mmol), CeCl3 (250 mg, 1.0 mmol), methylmagnesium bromide 90 
(0.7 mL, 2.0 mmol, 3.0 M solution in Et2O), THF (2.5 mL) and 
NaBH4 (25 mg, 0.63 mmol), only one diastereomer (9) was 
detected by GC-MS. Pure 9 (62 mg, 69%) was obtained after 
filtration thought a pad of Al2O3 (hexane-EtOAc 95:5). IR (NaCl) 
2958, 2935, 2877, 1665, 1463 cm-1; 1H NMR (400 MHz, CDCl3, 95 
COSY, HSQC) δ 0.82 (t, J = 7.4 Hz, 3H, CH2CH3), 1.02 (d, J = 
6.2 Hz, 3H, CH3C4), 1.07 – 1.31 (m, 6H, CH3CH2, H-3, H-8, H-
9), 1.36-1.66 (m, 6H,  H-1, H-2, H-7, H-8, H-9), 1.83 (app d, J = 
12.7 Hz, 1H, H-7), 2.67 (td, J = 13.7, 2.7 Hz, 1H, H-6ax.), 2.92 (app 
d, J = 12.6 Hz, 1H, H-9a), 2.98 (m, 1H, H-4), 3.27 (app d, J = 13.7 100 
Hz, 1H, H-6eq.); 13C NMR (100.6 MHz, CDCl3) δ 11.7 (CH2CH3), 
17.8 (CH2), 18.8 (CH2), 19.3 (CH3C4), 25.2 (CH2), 25.4 (CH2), 
25.8 (CH2), 34.8 (CH2), 41.8 (C-1), 46.7 (C-4), 50.1 (C-6), 60.8 
(C-9a); MS-EI m/z 181 M+ (10), 167 (13), 166 (100), 152 (13), 110 
(11), 83 (17); [α]22D = –23.8 (c 1.0, CHCl3); HRMS calcd for 105 
C12H24N [M+H]+ 182.1903; found, 182.1907. 
 
(1S,4R,9aR)-4-Allyl-1-ethylquinolizidine, (10) and 
(1S,4S,9aR)-4-allyl-1-ethylquinolizidine, (9a-epi-207I).  
Following the general procedure, from lactam 9a-epi-6 (124 mg, 110 
0.6840 mmol), CeCl3 (340 mg, 1.37 mmol), allylmagnesium 
bromide (2.75 mL, 2.75 mmol, 1.0 M solution in Et2O), THF (3.0 
mL) and NaBH4 (33 mg, 0.86 mmol), a 1:1 diastereomeric mixture 
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of 10 and 9a-epi-207I (GC-MS) was obtained (75 mg, 54%). 
Compound 9a-epi-207I was isolated by column chromatography 
(Al2O3, hexane-EtOAc 95:5). 10:5 MS-EI m/z 206 (1), 167 (42), 
166 (100), 110 (54), 84 (20), 67 (23), 55 (42), 54 (20). 9a-epi-207I. 
IR (neat) 2958, 2928, 2856, 1450, 1119 cm-1; 1H NMR (400 MHz, 5 
CDCl3, TMS, NOE, COSY, HSQC) δ = 0.86 (t, 3H, J = 7.3 Hz, 
CH2), 1.13-1.74 (m, 13H, CH2CH3, H-1, H-2, H-3, H-7, H-8, H-
9), 2.04 (td, 1H, J = 9.6, 3.0 Hz, 1H, H-9a), 2.17 (m, 1H, CH2CH=), 
2.42 (m, 1H, CH2CH=), 2.50 (td, 1H, J = 11.3, 3.7 Hz, H-6ax.), 2.66 
(m, app dt, 1H, J = 11.3, 4.4 Hz, H-6eq.), 2.81 (m, 1H, H-4), 4.97-10 
5.06 (m, 2H, CH=CH2), 5.71 (dddd, J = 17.0, 10.1, 8.4, 6.1 Hz, 
1H, CH2CH=); 13C NMR (100.6 MHz) δ 10.8 (CH2CH3), 23.4 
(CH2), 24.9 (CH2), 25.0 (CH2), 26.1 (C-7), 27.3 (CH2), 27.4 
(CH2CH=), 31.1 (CH2), 43.2 (C-1), 52.9 (C-6), 58.4 (C-4), 59.8 
(C-9a), 115.8 (=CH2), 137.5 (-CH2CH=); [α]22D = +57.5 (c 0.75, 15 
CHCl3); MS-EI m/z 206 M (1), 167 (27), 166 (100), 110 (55), 84 
(17), 67 (21), 55 (37), 54 (20). HRMS calcd for C14H26N [M+H]+, 
208.2060; found, 208.2058. 
 
(1S,4S,9aR)-1-Ethyl-4-methylquinolizidine, (11) and 20 
(1S,4R,9aR)-1-ethyl-4-methylquinolizidine, (4-epi-11). 
Following the general procedure, from lactam 9a-epi-6 (90 mg, 
0.50 mmol), CeCl3 (250 mg, 1.0 mmol), methylmagnesium 
bromide (0.70 mL, 2.0 mmol, 3.0 M solution in Et2O), THF (3.0 
mL) and NaBH4 (25 mg, 0.63 mmol), a 1:1 diastereomeric mixture 25 
of 11 and 4-epi-11 (GC-MS) was obtained (46 mg, 48%). The 
amines proved to be unstable under chromatography conditions. 
11*. MS-EI: m/z 181 M+ (34), 180 (29), 166 (100), 152 (46), 138 
(35), 124 (47), 110 (48), 96 (49), 83 (90), 67 (30), 55 (74). C4-epi-
11*. MS-EI m/z 181 M+ (29), 180 (30), 166 (100), 152 (47), 138 30 
(37), 124 (46), 110 (42), 96 (50), 83 (88), 67 (32), 55 (78). 
Dimethylated product was detected in the GC-MS MS-EI m/z 195 
M (17), 181 (16), 180 (100), 124 (20), 110 (20), 84 (43), 83 (43), 
82 (21), 56 (23), 55 (37).  
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Perspectives; S. W. Pelletier, Ed.; Wiley: New York, 1986; Vol. 4, pp 
1-274. b) J. W. Daly, H. M. Garraffo and R. F. Spande. In The 
Alkaloids, G. A. Cordell, Ed.; Academic Press: San Diego, 1993; Vol. 
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J. Nat. Prod., 1993, 56, 1016-1038, and in bufonid toads of the genus 
Melanophryniscus, H. M. Garraffo, T. F. Spande, J. W. Daly, F. 
Baldessari and E. G. Gros, J. Nat. Prod., 1993, 56, 357-373. For the 
racemic synthesis of 1,4-disubstituted quinolizidines found in poison 
frog skins, see: P. Michel, A. Rassat, J. W. Daly and T. F. Spande, J. 
Org. Chem., 2000, 65, 8908-8918. 
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Theoretical calculations. 
Initial geometries were obtained using the PCMODEL program.23 
Further geometry optimizations were carried out using the 
Gaussian 03 suite of programs on an Compaq HPC320 computer,24 
at the Hartree-Fock (HF) level,25 and at the Becke’s three-40 
parameter hybrid functional with the Lee, Yang and Parr 
correlation functional (B3LYP) level,26 using the 6-31G(d) basis 
set.27 Analytical energy second derivatives were calculated at all 
optimized structures to confirm that these were minima. 
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